Subsidiary gets NPPA demand notice of Rs. 52.75 crore over MRP of Lanol 1000 mg injection
NPPA demand notice of Rs. 52.75 crore dated October 13, 2026 issued to 3 parties, including wholly-owned subsidiary Pure and Cure Healthcare, over pricing of Lanol 1000 mg injection 100ml.
By ScoutQuest · · 2 min read
- Total Demand Notice Amount
- Rs. 52.75 crore
- Overcharging Amount (Dec 2017 to Aug 2024)
- Rs. 18.95 crore
- Penalty and Interest
- Penalty Rs. 18.95 crore (100% of overcharged); interest up to October 30, 2026 Rs. 14.85 crore
What the company disclosed
The company informed the exchanges that Pure and Cure Healthcare Private Limited, its wholly-owned subsidiary, has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, dated October 13, 2026. The notice concerns the formulation "Lanol 1000 mg injection" 100ml. The company states the notice says the client fixed the MRP of the product in excess of the prescribed limits under the applicable provisions of The Drugs (Prices Control) Order, 2013, and that the notice relates to manufacturing/marketing without obtaining prior price approval from the Government of India as specified under Section 15 of The Drugs (Prices Control) Order, 2013.
The figures stated in the notice
- Total demand notice amount: Rs. 52.75 crore
- Overcharging amount for batches manufactured during December 2017 to August 2024: Rs. 18.95 crore
- Penalty amount: Rs. 18.95 crore, being 100% of the overcharged amount
- Interest amount up to October 30, 2026: Rs. 14.85 crore
Who the notice was issued to
- Three parties: Hetero Healthcare Limited as marketer, Abaris Healthcare Private Limited, and Pure and Cure Healthcare Private Limited as manufacturer
- The company states the prime responsibility to respond on the notice is that of Hetero Healthcare Limited, being the marketer of the product
What the company says about liability
The company states that in the ordinary course of business, it and its subsidiaries execute supply agreements with the marketing entity(ies) containing a clause that the marketing entity shall be solely held liable for violation of DPCO provisions, and for any penalty, fine, interest and other amount as may be specified by the regulatory or statutory authority, in the event of any discrepancy found in the maximum retail price of the supplied medicine.
Timing
The demand notice was received by the company on October 15, 2026 at 11:05 A.M.
More numbers
- Total demand notice amountRs. 52,74,68,193/-
- Overcharging amount for batches manufactured December 2017 to August 2024Rs. 18,94,80,649/-
- Penalty amountRs. 18,94,80,649/-
- Penalty as percentage of overcharged amount100%
- Interest amount up to October 30, 2026Rs. 14,85,06,895/-
- Number of parties to the demand noticethree (03)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.